Therapy » Resolution of the Experts’ Council “Perspective possibilities of using GRS drug in therapeutic practice”

Resolution of the Experts’ Council “Perspective possibilities of using GRS drug in therapeutic practice”

DOI: https://dx.doi.org/10.18565/therapy.2024.5.144-149

Martynov A.I. , Barbarash O.L., Kobalava Zh.D., Malyavin A.G., Boshchenko A.A., Vengerovskii A.I., Zateyshchikov D.A., Chesnikova A.I., Yakushin S.S., Kashtalap V.V., Khazanov V.A., Bykov V.V., Larchenko V.V.

MEMBERS OF THE EXPERTS’ COUNCIL:

MARTYNOV A.I. , MD, Dr. Sci. (Medicine), professor, academician of RAS, president of the Russian Scientific Medical Society of Internal Medicine (RSMSIM), professor of the Department of hospital therapy No. 1 of the Faculty of general medicine of Russian University of Medicine of the Ministry of Healthcare of Russia, Moscow
BARBARASH O.L., MD, Dr. Sci. (Medicine), professor, academician of RAS, director of the Research Institute of Complex Problems of Cardiovascular Diseases of the Ministry of Science and Higher Education of the Russian Federation, head of the Department of cardiology and cardiovascular surgery of Kemerovo State Medical University of the Ministry of Healthcare of Russia, vice-president of the Russian Society of Cardiology, chief cardiologist of the Siberian Federal District, Honored Scientist of the Russian Federation, Kemerovo
KOBALAVA ZH.D., MD, Dr. Sci. (Medicine), professor, corresponding member of RAS, vice-president of RSMSIM, head of the Department of internal medicine with courses of cardiology and functional diagnostics named after academician V.S. Moiseev of the Medical Institute of RUDN University, Moscow
MALYAVIN A.G., MD, Dr. Sci. (Medicine), professor, general secretary of RSMSIM, chief external expert – pulmonologist of the Ministry of Healthcare of Russia in the Central Federal District, professor of the Department of phthisiology and pulmonology of the Faculty of general medicine of Russian University of Medicine of the Ministry of Healthcare of Russia, Moscow
BOSHCHENKO A.A., MD, Dr. Sci. (Medicine), associate professor, deputy director for research work of the Research Institute of Cardiology of Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk
VENGEROVSKII A.I., MD, Dr. Sci. (Medicine), professor, professor of the Department of pharmacology of Siberian State Medical University of the Ministry of Healthcare of Russia, Honorary Figure of Russian Higher Education, Tomsk
ZATEYSHCHIKOV D.A., MD, Dr. Sci. (Medicine), professor, head of the Department of therapy, cardiology and functional diagnostics with a course of nephrology of Central State Medical Academy of the Administration of the President of the Russian Federation, head of the Primary Vascular Department of City Clinical Hospital No. 51 of the Department of Healthcare of Moscow, Moscow
CHESNIKOVA A.I., MD, Dr. Sci. (Medicine), professor, member of the presidium of RSMSIM, authorized representative of RSMSIM in the Southern Federal District, head of the Department of internal medicine No. 1 of Rostov State Medical University of the Ministry of Healthcare of Russia, chief external expert-therapist of the Southern Federal District, Rostov-on-Don
YAKUSHIN S.S., MD, Dr. Sci. (Medicine), professor, head of the Department of hospital therapy with a course of medical and social expertise of Academician I.P. Pavlov Ryazan State Medical University of the Ministry of Healthcare of Russia, Ryazan
KASHTALAP V.V., MD, Dr. Sci. (Medicine), professor, professor of the Department of cardiology and cardiovascular surgery of Kemerovo State Medical University of the Ministry of Healthcare of Russia, head of the Department of clinical cardiology of the Research Institute of Complex Problems of Cardiovascular Diseases of the Ministry of Science and Higher Education of the Russian Federation, chief investigator in clinical trials of the medicinal product Granik®, Kemerovo
KHAZANOV V.A., MD, Dr. Sci. (Medicine), professor, chairman of the board of directors of the IFAR group of companies, developer of the medicinal product Granik®, Tomsk
BYKOV V.V., MD, PhD (Medicine), head of Department of preclinical research of the IFAR group of companies, developer of the medicinal product Granik®, Tomsk
LARCHENKO V.V., MD, PhD (Medicine), head of the Department of clinical research of the IFAR group of companies, developer of the medicinal product Granik®, Tomsk

Abstract. Current resolution represents the key characteristics and peculiarities of an innovative drug development – a domestic pharmaceutical product for the treatment of a wide range of cardiovascular diseases, designated by GRS code. Mechanisms of action and spectrum of effects, results of clinical trials (CTs) of phases I and II, prospects for using the drug in therapeutic practice, as well as the main and additional directions of the planned phase III CTs are considered.
With the support of: Russian Scientific Medical Society of Internal Medicine (RSMSIM).

Keywords: GRS drug, soluble guanylate cyclase, pulmonary arterial hypertension, endothelial dysfunction, thrombosis, atherosclerosis

Read entire article

Literature

1. Вовк Е.И., Наумов А.В., Чудаков С.Ю. Эффективная и безопасная антиагрегантная терапия в общемедицинской практике. Врач скорой помощи. 2006; (1): 51–59. (Vovk E.I., Naumov A.V., Chudakov S.Yu. An effective and safe antiplatelet therapy in general practice. Vrach skoroy pomoshchi = Ambulance Doctor. 2006; (1): 51–59 (In Russ.)).

2. Суслина З.А., Танашян М.М., Домашенко М.А. Антитромботическая терапия ишемических нарушений мозгового кровообращения с позиций доказательной медицины. 2-е изд. М.: ООО «Медицинское информационное агентство». 2009; 224 с. (Suslina Z.A., Tanashyan M.M., Domashenko M.A. Antithrombotic therapy of ischemic disorders of cerebral circulation. 2nd ed. Moscow: Meditsinskoe informatsionnoe agenstvo = Medical News Agency. 2009; 224 pp. (In Russ.)).

ISBN: 978-5-8948-1710-1. EDN: TOMWDJ.

3. Кашталап В.В., Седых Д.Ю. Эффективная антитромботическая терапия при мультифокальном атеросклерозе. РМЖ. Медицинское обозрение. 2024; 8(1): 42–47. (Kashtalap V.V., Sedykh D.Yu. Effective antithrombotic therapy in multifocal atherosclerosis. Russkiy meditsisnkiy zhurnal. Meditsinskoye obozreniye = Russian Medical Journal. Medical Review. 2024; 8(1): 42–47 (In Russ.)).

https://doi.org/10.32364/2587-6821-2024-8-1-7. EDN: GZNPBF.

4. Айнетдинова Д.Х., Удовиченко А.Е., Сулимов В.А. Роль антитромбоцитарной терапии в первичной и вторичной профилактике сердечно-сосудистых заболеваний. Эффективная фармакотерапия в кардиологии и ангиологии. 2007; (6): 38–42. (Aynetdinova D.Kh., Udovichenko A.E., Sulimov V.A. The role of antiplatelet therapy in primary and secondary prevention of cardiovascular diseases. Effektivnaya farmakoterapiya v kardiologii i angiologii = Effective Pharmacotherapy in Cardiology and Angiology. 2007; (6): 38–42 (In Russ.)). EDN: XTMETJ.

5. Кашталап В.В. Медикаментозная терапия артериальной гипертонии и дислипидемии: возможности препарата Липертанс (на примере клинического наблюдения). Российский кардиологический журнал. 2022; 27(11): 68–75. (Kashtalap V.V. Therapy for hypertension and dyslipidemia: Potential of Lipertans (on the example of a clinical observation). Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2022; 27(11): 68–75).

https://doi.org/10.15829/1560-4071-2022-5285. EDN: DXSNGE.

6. Stalker T.J., Newman D.K., Ma P. et al. Platelet signaling. Handb Exp Pharmacol. 2012; (210): 59–85.

https://doi.org/10.1007/978-3-642-29423-5_3. PMID: 22918727. PMCID: PMC4785017.

7. Sandner P., Zimmer D.P., Milne G.T. et al. Soluble guanylate cyclase stimulators and activators. Handb Exp Pharmacol. 2021; (264): 355–94.

https://doi.org/10.1007/164_2018_197. PMID: 30689085.

8. Граник В.Г., Рябова С.Ю., Паршин В.А., Михайлова Л.А., Григорьев Н.Б. (ООО «Протон»). Патент Российской Федерации RU 2483066. МПК C07D413/06. Новое антитромботическое и антиатеросклеротическое средство и способ его получения (варианты). Заявлено 08.11.2011, опубл. 27.05.2013. (Granik V.G., Ryabova S.Yu., Parshin V.A., Mikhailova L.A., Grigoriev N.B. (Proton LLC). Patent of the Russian Federation RU 2483066. IPC C07D413/06. New antithrombotic and antiatherosclerotic agent and method of its preparation (options). Announced 11/08/2011, publ. 05/27/2013 (In Russ.)).

9. Быков В.В., Смольякова В.И., Чернышева Г.А. с соавт. Влияние нового антитромботического средства GRS – стимулятора растворимой гуанилатциклазы на эндотелиальную дисфункцию у крыс после инфаркта миокарда. Бюллетень экспериментальной биологии и медицины. 2021; 172(12): 707–710. (Bykov V.V., Smol’yakova V.I., Chernysheva G.A. et al. Effects of a new antithrombotic drug GRS, a soluble guanylate cyclase stimulator, on endothelial dysfunction in rats with myocardial infarction. Byulleten’ eksperimental’noj biologii i mediciny = Bulletin of Experimental Biology and Medicine. 2021; 172(12): 707–710 (In Russ.)).

https://doi.org/10.47056/0365-9615-2021-172-12-707-710. EDN: ASERIY.

10. Bykov V.V., Birulina Yu.G., Nosarev A.V. et al. Antihypertensive effects of a soluble guanylate cyclase stimulator. Bull Exp Biol Med. 2022; 174(1): 41–45.

https://doi.org/10.1007/s10517-022-05643-8. PMID: 36437315.

11. Быков В.В., Чернышева Г.А., Смольякова В.И. с соавт. Антиагрегантная активность нового производного индолинона. Экспериментальная и клиническая фармакология. 2019; 82(7): 10–13. (Bykov V.V., Chernysheva G.A., Smol’yakova V.I. et al. Antiplatelet activity of a new indolinone derivative. Eksperimental’naya i klinicheskaya farmakologiya = Experimental and Clinical Pharmacology. 2019; 82(7): 10–13 (In Russ.)).

https://doi.org/10.30906/0869-2092-2019-82-7-10-13. EDN: KAYKAT.

12. Быков В.В., Быкова А.В., Станкевич С.А. с соавт. Фармакологические эффекты нового стимулятора растворимой гуанилатциклазы при экспериментальной легочной артериальной гипертензии. Бюллетень сибирской медицины. 2023; 22(1): 14–22. (Bykov V.V., Bykova A.V., Stankevich S.A. et al. Pharmacological effects of a new soluble guanylate cyclase stimulator in experimental pulmonary arterial hypertension. Byulleten’ sibirskoy meditsiny = Bulletin of Siberian Medicine. 2023; 22(1): 14–22 (In Russ.)).

https://doi.org/10.20538/1682-0363-2023-1-14-22. EDN: KTUVCO.

13. Bykov V.V., Bykova A.V., Dzyuman A.N. et al. Anti-atherosclerotic action of a new stimulator of soluble guanylate cyclase in an experiment. Bull Exp Biol Med. 2022; 174(3): 333–36.

https://doi.org/10.1007/s10517-023-05703-7. PMID: 36723753.

14. Быков В.В., Быкова А.В., Алиев О.И. с соавт. Влияние нового стимулятора растворимой гуанилатциклазы на агрегацию тромбоцитов и функции сосудистого эндотелия при экспериментальном ишемическом инсульте на фоне артериальной гипертензии. Артериальная гипертензия. 2022; 28(6): 710–717. (Bykov V.V., Bykova A.V., Aliev O.I. et al. Influence of a new stimulator of soluble guanylate cyclase on platelet aggregation and vascular endothelial function in experimental ischemic stroke against the background of arterial hypertension. Arterial’naya gipertenziya = Arterial Hypertension. 2022; 28(6): 710–717 (In Russ.)).

https://doi.org/10.18705/1607-419X-2022-28-6-710-717. EDN: CMZCLN.

Resolution of the Experts’ Council “Perspective possibilities of using GRS drug in therapeutic practice”

Literature

Similar Articles